Q-omics provides the consensus-scored TFEC profile across patient tissues and cancer cell-line models. TFEC expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TFEC is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TFEC RNA expression shows 18,472 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where TFEC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFEC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFEC survival associations across molecular data types. TFEC RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFEC RNA expression–survival associations across cancer types. High TFEC expression shows unfavorable associations in UVM and LGG, but favorable associations in KIRC, SKCM, KIRP and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TFEC RNA expression.
This table summarizes TFEC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TFEC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFEC shows lower tumor expression in LUSC, LUAD and KICH and higher tumor expression in KIRC, HNSC and STAD. The KIRC box plot shows higher TFEC RNA expression in tumor versus normal tissue (log2 FC = +1.542, t-test p < 0.001).
This table shows molecular features associated with TFEC in patient tissues and cancer cell lines. In patient samples, TFEC shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TFEC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
